New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President

Kyowa Kirin President Nobuo Hanai The launch of a new company tasked with the regulatory filing of an authorized Nesp (darbepoetin alfa) biosimilar is an effective business strategy that would “broaden options” for Kyowa Hakko Kirin, President Nobuo Hanai said...read more